You just read:

FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A

News provided by

BioMarin Pharmaceutical Inc.

Oct 26, 2017, 08:30 ET